FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase

Denmeade, 2004, Development of prostate cancer treatment: the good news, Prostate, 58, 211, 10.1002/pros.10360 Hsing, 2000, International trends and patterns of prostate cancer incidence and mortality, Int. J. Cancer, 85, 60, 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B Krongrad, 1998, The significance of changing trends in prostate cancer incidence and mortality, Semin. Urol. Oncol., 16, 30 Kent, 2003, The patient with hormone-refractory prostate cancer: determining who, when, and how to treat, Urology, 62, 134, 10.1016/j.urology.2003.09.005 Basler, 2004, Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention, J. Urol., 171, S59, 10.1097/01.ju.0000107839.06670.27 Pak, 2002, Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial, Integr. Cancer Ther., 1, 338, 10.1177/1534735402238186 Kyprianou, 2000, Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis, Cancer Res., 60, 4550 Fujita, 1994, Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite, J. Antibiot. (Tokyo), 47, 208, 10.7164/antibiotics.47.208 Azuma, 2002, Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models, Cancer Res., 62, 1410 Azuma, 2003, Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment, J. Urol., 169, 2372, 10.1097/01.ju.0000064938.32318.91 Yanagawa, 1998, FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo, J. Immunol., 160, 5493, 10.4049/jimmunol.160.11.5493 Hoshino, 1996, FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A, Transplant. Proc., 28, 1060 Chiba, 1998, FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing, J. Immunol., 160, 5037, 10.4049/jimmunol.160.10.5037 Hwang, 1999, FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation, Circulation, 100, 1322, 10.1161/01.CIR.100.12.1322 Nagahara, 2002, T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2, Br. J. Pharmacol., 137, 953, 10.1038/sj.bjp.0704970 Kahan, 2003, Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study, Transplantation, 76, 1079, 10.1097/01.TP.0000084822.01372.AC Bohler, 2003, Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine, Int. J. Clin. Pharmacol. Ther., 41, 482, 10.5414/CPP41482 Sonoda, 2001, FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells, Biochem. Biophys. Res. Commun., 281, 282, 10.1006/bbrc.2001.4352 Wang, 1999, Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation, Prostate, 40, 50, 10.1002/(SICI)1097-0045(19990615)40:1<50::AID-PROS6>3.0.CO;2-N Yoshioka, 1999, Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells, Cancer Res., 59, 2004 Banyard, 2000, Motility and invasion are differentially modulated by Rho family GTPases, Oncogene, 19, 580, 10.1038/sj.onc.1203338 Fritz, 1999, Rho GTPases are over-expressed in human tumors, Int. J. Cancer, 81, 682, 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B Wang, 2004, Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells, Oncogene, 23, 474, 10.1038/sj.onc.1207128 Subauste, 2000, Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas, J. Biol. Chem., 275, 9725, 10.1074/jbc.275.13.9725 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Mareel, 2003, Clinical, cellular, and molecular aspects of cancer invasion, Physiol. Rev., 83, 337, 10.1152/physrev.00024.2002 Engbring, 2003, The basement membrane matrix in malignancy, J. Pathol., 200, 465, 10.1002/path.1396 Pupa, 2002, New insights into the role of extracellular matrix during tumor onset and progression, J. Cell. Physiol., 192, 259, 10.1002/jcp.10142 Kaibuchi, 1999, Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells, Annu. Rev. Biochem., 68, 459, 10.1146/annurev.biochem.68.1.459 Van Aelst, 1997, Rho GTPases and signaling networks, Genes Dev., 11, 2295, 10.1101/gad.11.18.2295 Mackay, 1998, Rho GTPases, J. Biol. Chem., 273, 20685, 10.1074/jbc.273.33.20685 Sahai, 2002, RHO-GTPases and cancer, Nat. Rev. Cancer, 2, 133, 10.1038/nrc725 Evers, 2000, Rho family proteins in cell adhesion and cell migration, Eur. J. Cancer, 36, 1269, 10.1016/S0959-8049(00)00091-5 Tedesco-Silva, 2004, FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation, Transplantation, 77, 1826 Pan, 2004, Expression of seven main Rho family members in gastric carcinoma, Biochem. Biophys. Res. Commun., 315, 686, 10.1016/j.bbrc.2004.01.108 Permpongkosol, 2002, Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis, Int. J. Cancer, 98, 167, 10.1002/ijc.10178 Dowling, 1998, Systemic treatment for prostate cancer, Cancer Treat. Rev., 24, 283, 10.1016/S0305-7372(98)90062-7 Somlyo, 2000, Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells, Biochem. Biophys. Res. Commun., 269, 652, 10.1006/bbrc.2000.2343